We have developed two platforms: (1) innovative HSV-1 based oncolytic virus and (2) mRNA-based (including self-amplifying RNA/saRNA) therapeutics, aiming to elicit robust and durable anti-tumor immune response against solid tumors.

Both platforms exhibit a high degree of complementarity via a mechanism of Heterologous Prime-Boost. Yet each platform has ‘plug-to-play’ features to independently develop novel therapies against cancer & other indications. This combination approach presents a unique opportunity to elevate tumor vaccine immunotherapy to an unprecedented level.

Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.